We’re thrilled to have received funding of €4 million from Horizon 2020, the biggest research and innovation program in the European Union. Donated in June 2015, under grant agreement no 672570, our gift from Horizon 2020 is being used to fund a three-year project whose goal is to achieve final evidence for the clinical utility of MammaPrint®.
Our overall objective is to meet the reimbursement requirements in each targeted market and thereby gain comprehensive uptake by international clinical guideline committees and reimbursement bodies. As a result, many more breast cancer patients will potentially have access to the MammaPrint test. The MoTriColor study, part of the Horizon 2020 grant, is for the development of colon cancer subtypes. Further information can be viewed at motricolor.eu.